1. Mariotto, A.B., Etzioni, R., Hurlbert, M., Penberthy, L. & Mayer, M. Estimation of the number of women living with metastatic breast cancer in the united states. Cancer Epidemiol Biomarkers Prev26, 809–815 (2017). doi: 10.1158/1055-9965.Epi-16-0889
2. Gong, Y., Liu, Y.R., Ji, P., Hu, X. & Shao, Z.M. Impact of molecular subtypes on metastatic breast cancer patients: A seer population-based study. Sci Rep7, 45411 (2017). doi: 10.1038/srep45411
3. Malmgren, J.A., Mayer, M., Atwood, M.K. & Kaplan, H.G. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010. Breast Cancer Res Treat167, 579–590 (2018). doi: 10.1007/s10549-017-4529-5
4. Burstein, H.J., et al. Endocrine treatment and targeted therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO guideline update. J Clin Oncol0, JCO.21.01392 (2021). doi: 10.1200/jco.21.01392
5. VanArsdale, T., Boshoff, C., Arndt, K.T. & Abraham, R.T. Molecular pathways: Targeting the cyclin D–CDK4/6 axis for cancer treatment. Clin Cancer Res21, 2905–2910 (2015)
6. Finn, R.S., et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med375, 1925–1936 (2016) doi: 10.1056/NEJMoa1607303
7. Hortobagyi, G.N., et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med375, 1738–1748 (2016) doi: 10.1056/NEJMoa1609709
8. Tripathy, D., et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial. Lancet Oncol19, 904–915 (2018) doi: 10.1016/s1470-2045(18)30292-4
9. Goetz, M.P., et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol35, 3638–3646 (2017) doi: 10.1200/jco.2017.75.6155
10. Turner, N.C., et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med379, 1926–1936 (2018) doi: 10.1056/NEJMoa1810527
11. Slamon, D.J., et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med382, 514–524 (2019) doi: 10.1056/NEJMoa1911149
12. Sledge, G.W., Jr, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor–positive, ERBB2-negative breast cancer that progressed on endocrine therapy—MONARCH 2: A randomized clinical trial. JAMA Oncol6, 116–124 (2020) doi: 10.1001/jamaoncol.2019.4782
13. Finn, R.S., et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol16, 25–35 (2015) doi: 10.1016/s1470-2045(14)71159-3
14. Slamon, D.J., et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALESSA-3. J Clin Oncol36, 2465–2472 (2018) doi: 10.1200/jco.2018.78.9909
15. Hortobagyi, G.N., et al. Overall survival (OS) results from the phase III MONALEESA-2 (ml-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer (ABC) treated with endocrine therapy (ET) & ribociclib (RIB). Ann Oncol32, S1290-S1291 (2021) doi: 10.1016/j.annonc.2021.08.2090
16. Im, S.-A., et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med381, 307–316 (2019) doi: 10.1056/NEJMoa1903765
17. Cardoso, F., et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)†. Ann Oncol29, 1634–1657 (2018) doi: 10.1093/annonc/mdy192
18. André, F., et al. Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. N Engl J Med380, 1929–1940 (2019) doi: 10.1056/NEJMoa1813904
19. Baselga, J., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med366, 520–529 (2012) doi: 10.1056/NEJMoa1109653
20. Princic, N., et al. Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, hEGFR-2 negative metastatic breast cancer. Curr Med Res Opin35, 73–80 (2019) doi: 10.1080/03007995.2018.1519500
21. Lindeman, G.J., et al. Results from Veronica: A randomized, phase II study of second-/third-line venetoclax (ven) + fulvestrant (f) versus f alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (la/mbc). J Clin Oncol39, 1004–1004 (2021) doi:10.1200/JCO.2021.39.15_suppl.1004
22. Bardia, A., et al. Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (MBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial. (2021)
23. Brett, J.O., Spring, L.M., Bardia, A. & Wander, S.A. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res23, 85 (2021) doi: 10.1186/s13058-021-01462-3
24. Thangavel, C., et al. Therapeutically activating RB: Reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer18, 333–345 (2011) doi:10.1530/ERC-10-0262
25. Finn, R.S., et al. Biomarker analyses of response to cyclin-dependent kinase 4/6 inhibition and endocrine therapy in women with treatment-naïve metastatic breast cancer. Clin Cancer Res26, 110–121 (2020) doi:10.1158/1078-0432.Ccr-19-0751
26. Taylor-Harding, B., et al. Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS. Oncotarget6, 696–714 (2015) doi:10.18632/oncotarget.2673
27. Roberto, M., et al. Cdk4/6 inhibitor treatments in patients with hormone receptor positive, HER2 negative advanced breast cancer: Potential molecular mechanisms, clinical implications and future perspectives. Cancers (Basel)13(2021) doi:10.3390/cancers13020332
28. Fan, P., Wang, J., Santen, R.J. & Yue, W. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Res67, 1352–1360 (2007) doi:10.1158/0008-5472.Can-06-1020
29. Basile, D., et al. First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study. Breast57, 104–112 (2021) doi: 10.1016/j.breast.2021.02.015
30. Bardia, A., et al. Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR(+)/HER2(-) advanced breast cancer after progression on CDK4/6 inhibitors (triniti-1). Clin Cancer Res27, 4177–4185 (2021) doi:10.1158/1078-0432.Ccr-20-2114
31. O’Brien, N.A., et al. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer. Breast Cancer Res22, 89 (2020) doi: 10.1186/s13058-020-01320-8
32. Clark, A.S., Makhlin, I. & DeMichele, A. Setting the pick: Can PI3K inhibitors circumvent CDK4/6 inhibitor resistance? Clin Cancer Res27, 371–373 (2021) doi: 10.1158/1078-0432.Ccr-20-3624
33. Dhakal, A., et al. Outcome of everolimus-based therapy in hormone-receptor-positive metastatic breast cancer patients after progression on palbociclib. Breast Cancer (Auckl)14, 1178223420944864–1178223420944864 (2020) doi: 10.1177/1178223420944864
34. Cook, M.M., et al. Everolimus plus exemestane treatment in patients with metastatic hormone receptor-positive breast cancer previously treated with CDK4/6 inhibitor therapy. Oncologist26, 101–106 (2021) doi.org/10.1002/onco.13609
35. Rozenblit, M., et al. Patterns of treatment with everolimus exemestane in hormone receptor-positive her2-negative metastatic breast cancer in the era of targeted therapy. Breast Cancer Res23, 14 (2021) doi:10.1186/s13058-021-01394-y
36. Rugo, H.S., et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLIEVE): One cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol22, 489–498 (2021) doi:10.1016/s1470-2045(21)00034-6
37. van Ommen-Nijhof, A., et al. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: Study protocol for a randomized controlled trial. BMC Cancer18, 1146 (2018) 10.1186/s12885-018-4978-1
38. Kalinsky, K., et al. Abstract ot3-05-09: A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, her2 negative breast cancer (maintain trial). Cancer Res78, OT3-05-09-OT03-05-09 (2018) 10.1158/1538–7445.Sabcs17-ot3-05-09
39. Ciruelos, E., et al. Abstract ot-13-04: Solti-1716. Targeting non-luminal disease by PAM50 with pembrolizumab + paclitaxel in hormone receptor-positive/HER2-negative advanced/metastatic breast cancer patients who have progressed on or after CDK 4/6 inhibitor treatment (TATEN trial). Cancer Res81, OT-13-04-OT-13-04 (2021) 10.1158/1538–7445.Sabcs20-ot-13-04